Last week the Federal Circuit reversed the decision by Judge Gilstrap of E.D. Texas to proceed with litigation, rather than stay the litigation pending the U.S. Patent Trial and Appeal Board (“PTAB”) review of the asserted patents under the Transitional Program for Covered Business Method Patents (“CBM”). This is the first time the Federal Circuit
RANDomness
By Essential Patent Blog on
Posted in RANDomness
- Last week, the U.S. Supreme Court issued its unanimous opinion in Association for Molecular Pathology v. Myriad Genetics, where the Court held that Myriad’s claims on isolated genes were not patent-eligible subject matter under Section 101. Patently-O has a good round-up on the decision, as well as some thoughts from various members of
…